To identify patients who were still at risk for HCC after HCV eradication, the prior study demonstrated that higher AFP level at 24 weeks after the end of IFN therapy was the predictor of HCC incidence [21]. The gene discussed is IFNA1; the disease is hepatocellular carcinoma.